Femoropopliteal Artery Stent Thrombosis

Original Title: Femoropopliteal Artery Stent Thrombosis. Report from the Excellence in Peripheral Artery Disease Registry. Reference: Subhash Banerjee et al. Circ Cardiovasc Interv. 2016 Feb;9(2):e002730.

 

There is limited information on peripheral stent thrombosis and involved factors.

This study analyzed 604 stent procedures in femoropopliteal territory form the multicenter registry “Excellence in Peripheral Artery Disease”.

Stent thrombosis occurred in 26 of the 604 patients (4.3%) at median 6 month follow up post procedure.

Stent thrombosis was more frequent in men and when the lesion originally treated was a chronic total occlusion.

There were no differences in stent thrombosis between drug-coated and bare metal stents (4.4% vs 3.4%; p=0.55) but there were differences between self-expandable covered stents vs. conventional bare metal stents (10.6% vs 3.4%; p=0.02).

Thrombosis was associated to a much higher risk of adverse events over the same treated limb (HR, 4.99; CI 95% 2.31 to 10.77; p<0.001).

Multivariable analysis showed that chronic total occlusion (OR, 3.46; IC 95% 0.98 a 12.20; p=0.05) and in-stent restenosis (OR, 5.30; IC 95%, 1.83 a 15.32; p=0.002) were independently associated with stent thrombosis.

Conclusion
This multicenter registry of peripheral intervention showed that femoropopliteal stent thrombosis is 4.3% and is associated to the treatment of chronic total occlusions and restenosis of previous stents. Thrombosis is strongly associated to adverse events in this lower limb.

More articles by this author

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...